Abstract: Abstract:Objective To investigate the serum concentrations of Ang2 and VEGF in patients with NSCLC,and to provide some guidances in early diagnosis, progression evaluation and prognosis prediction for NSCLC. Methods A total of 82 patients with untreated NSCLC were selected, ELISA was used to measure the serum VEGF and Ang2 levels in all cases. Results Ang2 and VEGF levels in NSCLC group were significantly higher than those in the control group ［Ang2： (1326.8 ± 942.9)pg/ml vs. (445.0 ± 213.0) pg/ml, P<0.01; VEGF： (846.8 ± 459.6)pg/ml vs. (691.3 ± 369.6) pg / ml, P<0.05］. Serum Ang2 significantly increased in the early stage and terminal advanced stage of NSCLC, but showed no difference among various advanced subgroups. Serum VEGF levels began to increase with the progression of TNM staging from mid-stage, but not in early stage NSCLC, The diameter of intrapulmonary primary tumor was positively correlated with the serum VEGF levels in non-metastatic NSCLC. COX regression analysis showed that TNM staging and VEGF levels were independent risk factors on survival prognosis (P<0.05). Conclusion Serum Ang2 and VEGF levels were significantly higher in NSCLC. Detecting serum Ang2 is more valuable for aiding early diagnosis than VEGF. Serum VEGF can be used to evaluate tumor progression better than Ang2 in the advanced stage NSCLC. An elevation in Ang2 in a late stage can show that the patient has entered a terminal stage.